Very tight vs. tight control: what should be the criteria for pharmacologic therapy dose adjustment in diabetes in pregnancy? Evidence from randomized controlled trials
- PMID: 29125636
- DOI: 10.1111/aogs.13257
Very tight vs. tight control: what should be the criteria for pharmacologic therapy dose adjustment in diabetes in pregnancy? Evidence from randomized controlled trials
Abstract
Introduction: There is inconclusive evidence from randomized controlled trials (RCTs) to support any specific criteria for pharmacologic therapy dose adjustment in diabetes in pregnancy. Our objective was to analyze the criteria for dose adjustment of pharmacologic treatment for diabetes mellitus (DM) in pregnancy.
Material and methods: Data sources: MEDLINE, OVID and Cochrane Library were searched from their inception to September 2017. Selection criteria included all trials of DM in pregnancy managed by oral hypoglycemic agents or insulin reporting criteria for pharmacologic therapy dose adjustment. RCTs in women with pregestational DM and gestational DM (GDM) were included. For each trial, data regarding glucose values used for pharmacologic therapy dose adjustment were extracted and carefully reviewed.
Results: Of 51 RCTs on therapy for GDM or pregestational DM, 17 (4230 women) were included as they reported criteria for pharmacologic therapy dose adjustment. Most of them (88%, 15/17) included women with GDM only. For RCTs including women with GDM, 12/16 (75%) used the two-step approach, three (19%) the one-step approach and one (6%) either the one- or two-step approach. Regarding the type of initial therapy, 13 (77%) RCTs used different types and doses of insulin; nine (53%) used metformin; five (30%) used glyburide; and one (6%) used placebo. In most RCTs, glucose monitoring was assessed four times daily, i.e. fasting (all RCTs) and two hours (15 RCTs, 88%) after each of the three main meals - breakfast, lunch, and dinner. For fasting glucose target, all used a value <105 mg/dL; nine (53%) used 95 mg/dL as target. Of the 15 RCTs using a two-hour postprandial value as target, 11 (73%) had 120 mg/dL as cutoff. Regarding the criteria for pharmacologic therapy dose adjustment, we found six different criteria. The majority of RCTs (9/17, 53%) used either one or two values per week higher than the target values, of which two-thirds used only one value (35% of total), and one-third (18% of total) two values. Five RCTs (29%) used >50%, one (6%) >30%, and one (6%) >20% of the values higher than the target value; one (6%) used the appearance of glycosuria.
Conclusions: When evaluating RCTs which included criteria for pharmacologic GDM therapy dose adjustment, the most common criterion for diagnosis was the two-step test, and the most common used therapies were insulin and metformin. Regarding glucose monitoring, the most common frequency was four times per day, fasting and two hours after each main meal, using as target glucose values 95 and 120 mg/dL, respectively. Importantly, we found six different criteria for pharmacologic GDM therapy dose adjustment, with the majority using very tight criteria of either one or two values per week higher than the target values, of which two-thirds used only one value, and one-third used two values.
Keywords: Diabetes; diabetes mellitus; gestational diabetes mellitus; insulin; metformin; pregnancy.
© 2017 Nordic Federation of Societies of Obstetrics and Gynecology.
Similar articles
-
Which criteria should be used for starting pharmacologic therapy for management of gestational diabetes in pregnancy? Evidence from randomized controlled trials.J Matern Fetal Neonatal Med. 2019 Sep;32(17):2905-2914. doi: 10.1080/14767058.2018.1449203. Epub 2018 Mar 20. J Matern Fetal Neonatal Med. 2019. PMID: 29506426
-
[Clinical use of continuous glucose monitoring system in gestational diabetes mellitus and type 2 diabetes complicated with pregnancy].Zhonghua Fu Chan Ke Za Zhi. 2014 Aug;49(8):579-83. Zhonghua Fu Chan Ke Za Zhi. 2014. PMID: 25354857 Chinese.
-
Insulin and glyburide therapy: dosage, severity level of gestational diabetes, and pregnancy outcome.Am J Obstet Gynecol. 2005 Jan;192(1):134-9. doi: 10.1016/j.ajog.2004.07.011. Am J Obstet Gynecol. 2005. PMID: 15672015
-
Randomized controlled trial of insulin detemir versus NPH for the treatment of pregnant women with diabetes.Am J Obstet Gynecol. 2015 Sep;213(3):426.e1-7. doi: 10.1016/j.ajog.2015.06.010. Epub 2015 Jun 9. Am J Obstet Gynecol. 2015. PMID: 26070699 Clinical Trial.
-
Comparative Efficacy and Safety of Metformin, Glyburide, and Insulin in Treating Gestational Diabetes Mellitus: A Meta-Analysis.J Diabetes Res. 2019 Nov 4;2019:9804708. doi: 10.1155/2019/9804708. eCollection 2019. J Diabetes Res. 2019. PMID: 31781670 Free PMC article.
Cited by
-
From Standard of Care to Emerging Innovations: Navigating the Evolution of Pharmacological Treatment of Gestational Diabetes.Am J Perinatol. 2025 Jul;42(9):1127-1134. doi: 10.1055/a-2407-0905. Epub 2024 Sep 27. Am J Perinatol. 2025. PMID: 39333039 Review.
-
Recent advances in the antepartum management of diabetes.F1000Res. 2019 May 8;8:F1000 Faculty Rev-622. doi: 10.12688/f1000research.15795.1. eCollection 2019. F1000Res. 2019. PMID: 31119029 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical